Cinctive Capital Management LP Makes New $8.50 Million Investment in Becton, Dickinson and Company (NYSE:BDX)

Cinctive Capital Management LP acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 37,478 shares of the medical instruments supplier’s stock, valued at approximately $8,503,000.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $25,000. Sierra Ocean LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter worth $29,000. Picton Mahoney Asset Management grew its position in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 54 shares during the period. Hopwood Financial Services Inc. acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth about $39,000. Finally, Versant Capital Management Inc raised its holdings in shares of Becton, Dickinson and Company by 54.1% in the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 73 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Piper Sandler lifted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, Barclays raised their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $226.04 on Wednesday. The firm has a market cap of $64.90 billion, a P/E ratio of 37.55, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The business’s 50 day moving average is $231.38 and its 200-day moving average is $231.62. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Shareholders of record on Monday, March 10th were given a dividend of $1.04 per share. The ex-dividend date was Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.84%. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $235.00, for a total transaction of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares of the company’s stock, valued at approximately $3,807,235. This represents a 4.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Richard Byrd sold 1,940 shares of the business’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total value of $436,325.40. Following the completion of the transaction, the executive vice president now directly owns 7,411 shares of the company’s stock, valued at approximately $1,666,808.01. This trade represents a 20.75 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.